CI
ALXN

CX Institutional’s Alexion Pharmaceuticals ALXN Stock Holding History

CX Institutional’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-452
Closed -$83K – 989
2021
Q2 		$83K Buy
452
+140
+45% +$24K 0.01% 469
2021
Q1 		$48K Buy
312
+48
+18% +$7.42K ﹤0.01% 502
2020
Q4 		$41K Buy
264
+78
+42% +$10K ﹤0.01% 478
2020
Q3 		$21K Buy
186
+55
+42% +$5.93K ﹤0.01% 538
2020
Q2 		$15K Buy
131
+71
+118% +$7.54K ﹤0.01% 508
2020
Q1 		$5K Sell
60
-21
-26% -$2.06K ﹤0.01% 564
2019
Q4 		$9K Buy
81
+53
+189% +$5.67K ﹤0.01% 450
2019
Q3 		$3K Sell
28
-30
-52% -$3.38K ﹤0.01% 707
2019
Q2 		$8K Sell
58
-50
-46% -$6.44K ﹤0.01% 539
2019
Q1 		$15K Buy
+108
New +$13.4K ﹤0.01% 423

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return